Akero Shows FGF21/GLP-1 Combo’s Potential In NASH And Type 2 Diabetes

 
• By Joseph Haas

Phase IIb data show that Akero’s efruxifermin on top of GLP-1 therapy is relatively safe and offers liver fat reductions and fibrosis improvements in NASH patients with type 2 diabetes.

Type 2 diabetes
Akero combo shows safety, efficacy in NASH patients with type 2 diabetes • Source: Shutterstock

More from Clinical Trials

More from R&D